TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39009116
Drug: Low high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low high-density lipoprotein levels (<1200 mmol/l)
Study: 39009312
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (up to a 21 mg daily dose over 12 weeks)
Study: 39009356
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil concentrate (KOC) 4 g/day for 24 weeks
Study: 39009368
Drug: Opioid prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid prescriptions at emergency department discharge
Study: 39009368
Drug: Smaller, cause-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller, cause-specific opioid prescriptions
Study: 39009709
Drug: Nilotinib (Tasigna)
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib (Tasigna) treatment for 1 year
Study: 39010171
Drug: Dexmedetomidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine nasal spray 0.2 µg/kg
Study: 39010171
Drug: Dexmedetomidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine nasal spray 0.5 µg/kg
Study: 39010748
Drug: Training to
Normalized name: Poloxamer 407/Simethicone 2%-0.12% Dental Paste [ORAJEL TODDLER TRAINING TOOTHPASTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training to deal with distractions and conflicting situations in activities of daily living after TBI
Study: 39192339
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial plus RB-PDT
Study: 39192339
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial plus sham RB-PDT
Study: 39012102
Drug: TRL1068 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRL1068 (administered via a single pre-surgical intravenous infusion in doses of 6, 15, and 30 mg/kg)
Study: 39012226
Drug: Pyrazinamide treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinamide treatment, dosage and duration not specified
Study: 39012717
Drug: Setrusumab 20
Normalized name: Setrusumab
DrugBank: Setrusumab (DB14778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setrusumab 20 mg/kg
Study: 39012717
Drug: Setrusumab 8
Normalized name: Setrusumab
DrugBank: Setrusumab (DB14778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setrusumab 8 mg/kg
Study: 39012930
Drug: Personalized prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized prescription of pacing (PPoP) for 6 months
Study: 39012946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperglycemia with low HDL cholesterol
Study: 39012946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperglycemia with high systemic blood pressure
Study: 39013470
Drug: Allogeneic CD19-targeted
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic CD19-targeted CAR-T therapy
Study: 39013886
Drug: NeoAdjuvant ChemoTherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoAdjuvant ChemoTherapy (NACT) + Pembrolizumab (P)
Study: 39013886
Drug: NeoAdjuvant ChemoTherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoAdjuvant ChemoTherapy (NACT)
Study: 39014136
Drug: CRP quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP quartile Q1 (<8 mg/L)
Study: 39014136
Drug: CRP quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP quartile Q2 (8-28 mg/L)
Study: 39014136
Drug: CRP quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP quartile Q3 (>28-69 mg/L)
Study: 39014136
Drug: CRP quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP quartile Q4 (>69 mg/L)
Study: 39014448
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay)
Study: 39014498
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB (NB-UVB) combined with optimal topical therapy (OTT) for a minimum of 3 months and 8 to 16 weeks of NB-UVB
Study: 39014498
Drug: Optimal topical
Normalized name: Optima Plus Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal topical therapy (OTT) for 3 months
Study: 39014980
Drug: Primary control
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary control engagement coping (e.g., problem-solving)
Study: 39014980
Drug: Secondary control
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary control engagement coping (e.g., positive thinking)
Study: 39015065
Drug: Caregiver Global
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caregiver Global Impression of Change in memory or daily activities
Study: 39015674
Drug: Autologous Bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Bone Marrow-Derived Mononuclear Cell Infusion into Renal Arteries
Study: 39016024
Drug: Topical Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cannabidiol
Study: 39016381
Drug: Multimodal enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal enhanced recovery pathway including preoperative and postoperative nonopioid analgesia with oral acetaminophen, gabapentin, and ketorolac.
Study: 39016593
Drug: Molecular dihydrogen
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular dihydrogen (H2) inhalation therapy (3.6% H2 and 96.4% N2)
Study: 39016594
Drug: Linezolid (LZD)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid (LZD) treatment over 14 days
Study: 39017661
Drug: Oral microbiome
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiome in patients with oral cGVHD
Study: 39017661
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and gut microbiota overlap
Study: 39017661
Drug: Longitudinal trajectories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal trajectories of oral and gut microbiomes
Study: 39018038
Drug: Cendakimab 720
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendakimab 720 mg, once weekly
Study: 39018038
Drug: Cendakimab 720
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendakimab 720 mg, every 2 weeks
Study: 39018038
Drug: Cendakimab 360
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendakimab 360 mg, every 2 weeks
Study: 39018071
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (support for lactation, kangaroo care, and routine developmental therapies)
Study: 39018444
Drug: Quantifiable spike
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantifiable spike antibody (Ab)
Study: 39018444
Drug: Unquantifiable spike
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unquantifiable spike antibody (Ab)
Study: 39018532
Drug: 5-day nirmatrelvir-ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 5 days)
Study: 39018532
Drug: 10-day nirmatrelvir-ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 10 days)
Study: 39018898
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) pregabalin (150 mg once daily)
Study: 39018898
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) pregabalin (75 mg twice daily)
Study: 39019119
Drug: Low BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low BC (392 mg/day)
Study: 39019119
Drug: High BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High BC (784 mg/day)
Study: 39019203
Drug: Stellarex Drug-Coated
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellarex Drug-Coated Balloon (2 µg/mm)
Study: 39019639
Drug: Implant-based breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-based breast reconstruction
Study: 39019657
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of mRNA-1273
Study: 39019657
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination (dose or brand unspecified)
Study: 39019875
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/day (D-50)
Study: 39019875
Drug: Desvenlafaxine 100
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 100 mg/day (D-100)
Study: 39020305
Drug: Cenegermin t.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegermin t.i.d. (20 mcg/mL, 3 times daily)
Study: 39020305
Drug: Cenegermin b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegermin b.i.d. (20 mcg/mL, 2 times daily)
Study: 39020305
Drug: Vehicle (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (once daily or t.i.d.)
Study: 39020409
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (ET) for primary M3 occlusion
Study: 39020446
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two additional doses of COVID-19 vaccines 3 months apart
Study: 39020503
Drug: Guided Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Bone Regeneration (GBR) treatment
Study: 39020518
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab
Study: 39020518
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy and neoadjuvant chemotherapy
Study: 39022429
Drug: STOP group
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOP group (40,000 IU subcutaneous EPO combined with 20 mg/kg intravenous ferric carboxymaltose if Hb < 13 g/dL the day before surgery or at ICU admission, and RBC transfusion if Hb ≤ 8 g/dL)
Study: 39022700
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitor use as intraarterial (IA) bolus + intravenous (IV) infusion
Study: 39022796
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22, administered in 28-day cycles for a total of 12 cycles
Study: 39023063
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulants (OAC)
Study: 39023253
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus endocrine therapy for 2 years, followed by endocrine therapy for a total of at least 5 years.
Study: 39023253
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy only for at least 5 years.
Study: 39023253
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy only
Study: 39023418
Drug: Prescriptions for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins
Study: 39023538
Drug: Heparin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin anticoagulation (HA)
Study: 39023880
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg orally once daily for up to 52 weeks
Study: 39023880
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily for up to 52 weeks
Study: 39023900
Drug: 90 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 minutes per week of exercise therapy
Study: 39023900
Drug: 150 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 minutes per week of exercise therapy
Study: 39023900
Drug: 225 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 minutes per week of exercise therapy
Study: 39023900
Drug: 300 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 minutes per week of exercise therapy
Study: 39023900
Drug: 375 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 minutes per week of exercise therapy
Study: 39023900
Drug: 450 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 minutes per week of exercise therapy
Study: 39024037
Drug: Nivolumab (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks)
Study: 39024364
Drug: Early norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early norepinephrine (NE) administration
Study: 39024543
Drug: valoctocogene roxaparvovec
Normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: valoctocogene roxaparvovec (6 × 10^13 vg/kg infusion)
Study: 39024542
Drug: Once-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly carfilzomib (56 mg/m2) plus lenalidomide and dexamethasone (KRd56)
Study: 39024542
Drug: Twice-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27)
Study: 39024845
Drug: Active PSI-rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PSI-rTMS (10 Hz, 80% resting motor threshold, 5 daily sessions for 1 week, followed by weekly maintenance for 7 weeks)
Study: 39025066
Drug: ABO1020 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABO1020 (15 μg per dose, 2 doses, administered 28 days apart)
Study: 39025066
Drug: ABO1020 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABO1020 (1 or 2 doses)
Study: 39025092
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral antibiotics (coformulated amoxicillin 100 mg/kg per day and clavulanic acid 12.5 mg/kg per day for patients younger than 5 years; dicloxacillin 200 mg/kg per day for patients aged 5 years or older)
Study: 39025092
Drug: Initial intravenous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intravenous antibiotics (ceftriaxone 100 mg/kg per day in one dose)
Study: 39025264
Drug: nano-CBD cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-CBD cream
Study: 39025698
Drug: VAX-24 2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX-24 2.2 mcg dose
Study: 39025812
Drug: Evidence-based recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based recommendations for treatment following ACL rupture.
Study: 39025971
Drug: Milvexian (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (200 mg; twice daily for 5 days) with aspirin (325 mg for 5 days)
Study: 39025971
Drug: Milvexian (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (200 mg; twice daily for 5 days) with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Study: 39025971
Drug: Milvexian (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (200 mg; twice daily for 5 days) without aspirin or clopidogrel
Study: 39025971
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin (325 mg for 5 days)
Study: 39025971
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Study: 39025971
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without aspirin or clopidogrel
Study: 39026165
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal delivery system (GTDS) combined with Dexamethasone
Study: 39026266
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (40 min daily over three consecutive days)
Study: 39026266
Drug: Midazolam (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (active placebo, 40 min daily over three consecutive days)
Study: 39026306
Drug: Aripiprazole oral
Normalized name: aripiprazole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole oral solution (1 mg/mL, range: 2-20 mg, starting dose of 2 mg)
Study: 39026552
Drug: Treatment requirements
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment requirements in GCA patients
Study: 39026552
Drug: Treatment needs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment needs in PMR patients
Study: 39026620
Drug: Extracellular vesicles
Normalized name: Stem-cell derived extracellular vesicles
DrugBank: Stem-cell derived exosome vesicle products (DB15743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular vesicles (EVs) as a biological therapy for preventing postoperative AF
Study: 39027143
Drug: Dostarlimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (500 mg intravenously every three weeks for four doses, then 1000 mg every six weeks)
Study: 39027664
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (0.3 g inorganic nitrate twice/day)
Study: 39028043
Drug: Mobilisation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilisation with ankle movement treatment 3 times per week for 4 weeks
Study: 39028057
Drug: Cervical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical and thoracic mobilisation with conventional physical therapy
Study: 39028360
Drug: Open-loop (sensor-augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop (sensor-augmented pump) insulin therapy
Study: 39028412
Drug: SFX-01 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFX-01 300 mg BD for 28 days
Study: 39028763
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous dexamethasone
Study: 39028902
Drug: casirivimab/imdevimab 1200
Normalized name: casirivimab/imdevimab 1200 mg/10mL(300 mg/2.5mL x4)-1200 mg/10mL(300 mg/2.5mL x 4) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: casirivimab/imdevimab 1200 mg
Study: 39028916
Drug: HER-Vaxx plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER-Vaxx plus chemotherapy
Study: 39028918
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy, specific dosage and duration not available
Study: 39028918
Drug: Placebo control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control, specific dosage and duration not available
Study: 39028923
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) trastuzumab/pertuzumab (HP)
Study: 39028923
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) trastuzumab/pertuzumab (HP)
Study: 39029295
Drug: Sotorasib 960
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib 960 mg once daily
Study: 39029295
Drug: Sotorasib 240
Normalized name: sotorasib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotorasib 240 mg once daily
Study: 39029481
Drug: VLA15 (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLA15 (135 μg or 180 μg)
Study: 39030060
Drug: HEV239 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV239 (recombinant HEV vaccine)
Study: 39030060
Drug: Hepa-B (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepa-B (control vaccine)
Study: 39030062
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (repeat viral-load testing and empirical onward treatment)
Study: 39030919
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg daily for 10 weeks
Study: 39031449
Drug: ARFID-PTP (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARFID-PTP (two 2-hour individual treatment sessions with an optional booster session at 4-week follow-up)
Study: 39031824
Drug: Lenvatinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (20 mg daily) plus pembrolizumab (200 mg every 3 weeks; up to 35 cycles)
Study: 39031963
Drug: Cemiplimab (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (350 mg IV every 3 weeks for 5 cycles of 9 weeks/cycle, then 4 cycles of 12 weeks/cycle)
Study: 39032787
Drug: Plant-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based diet (PBD) with high potassium content delivered as a weekly food basket while continuing sodium zirconium cyclosilicate (SZC) for 3 weeks
Study: 39032926
Drug: Intermittently dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittently dosed relacorilant in combination with nab-paclitaxel
Study: 39032926
Drug: Nab-paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel monotherapy
Study: 39033046
Drug: Dual delayed-release
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual delayed-release esomeprazole (10 mg)
Study: 39033201
Drug: Nasal antiseptic
Normalized name: 3M Skin and Nasal Antiseptic
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal antiseptic solution containing povidone-iodine (n=25)
Study: 39033201
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (n=25)